Dr. Jackson is a senior resident in Neurosurgery at Johns Hopkins. He obtained his MD from the Johns Hopkins University School of Medicine. He completed his chief residency in June 2018 and is currently working as a postdoctoral fellow in neuro-oncology. His research interests focus on interactions between brain tumors and the host immune system, particularly local, regional, and systemic mechanisms of immune suppression Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.

Select Guide Rating

• 1. Peptide vaccines 2. Dendritic cell vaccines 3. Heat shock protein vaccines 4. Immune checkpoint blockade 5. Targeting myeloid cells in glioblastoma 6. Oncolytic viruses 7. CAR T cell therapy 8. Mechanisms of immune suppression in glioblastoma patients 9. Immunogenomics in glioblastoma

Dr. Jackson is a senior resident in Neurosurgery at Johns Hopkins. He obtained his MD from the Johns Hopkins University School of Medicine. He completed his chief residency in June 2018 and is currently working as a postdoctoral fellow in neuro-oncology. His research interests focus on interactions between brain tumors and the host immune system, particularly local, regional, and systemic mechanisms of immune suppression Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.

Select Guide Rating

• 1. Peptide vaccines 2. Dendritic cell vaccines 3. Heat shock protein vaccines 4. Immune checkpoint blockade 5. Targeting myeloid cells in glioblastoma 6. Oncolytic viruses 7. CAR T cell therapy 8. Mechanisms of immune suppression in glioblastoma patients 9. Immunogenomics in glioblastoma

Dr. Jackson is a senior resident in Neurosurgery at Johns Hopkins. He obtained his MD from the Johns Hopkins University School of Medicine. He completed his chief residency in June 2018 and is currently working as a postdoctoral fellow in neuro-oncology. His research interests focus on interactions between brain tumors and the host immune system, particularly local, regional, and systemic mechanisms of immune suppression Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons. Dr. Michael Lim is Chair of the Department of Neurosurgery at Stanford with clinical interests in brain tumors as well as trigeminal neuralgia. He has garnered numerous teaching awards and has successfully led multiple phase I-III clinical trials for immunotherapy in glioblastoma. He is a member of multiple organizations and has served on the executive committee of the Joint Tumor Section of the American Association of Neurological Surgeons and Congress of Neurological Surgeons.

Select Guide Rating

• 1. Peptide vaccines 2. Dendritic cell vaccines 3. Heat shock protein vaccines 4. Immune checkpoint blockade 5. Targeting myeloid cells in glioblastoma 6. Oncolytic viruses 7. CAR T cell therapy 8. Mechanisms of immune suppression in glioblastoma patients 9. Immunogenomics in glioblastoma